Fulgent Genetics, Inc.
FLGT · XNASCIK 1674930fmd_18XQ671PP8A18B1TJAD231AJDGServices · Services-Medical LaboratoriesTemplate: Standard
Coverage: Jan 01, 2014 to Sep 30, 2026, 48 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 18 | 19 | 21 | 33 | 422 | 993 | 619 | 289 | 283 | 323 |
| Rental revenue | – | – | – | 0 | 0 | 0 | 0 | 0 | – | – |
| Cost of revenue | 7 | 9 | 11 | 14 | 90 | 216 | 252 | 185 | 176 | 192 |
| Gross profit | 12 | 10 | 11 | 18 | 332 | 777 | 367 | 104 | 107 | 131 |
| Research and development | 4 | 4 | 6 | 7 | 12 | 24 | 29 | 41 | 49 | 54 |
| Selling, general and administrative | 7 | 9 | 10 | 12 | 30 | 75 | 150 | 130 | 124 | 160 |
| Total operating expenses | 11 | 14 | 16 | 19 | 42 | 101 | 188 | 300 | 181 | 222 |
| Operating income | 1 | (3) | (5) | (0) | 290 | 676 | 179 | (196) | (74) | (91) |
| Interest expense | – | – | – | – | 0 | 0 | 1 | 0 | (0) | 0 |
| Interest and investment income | – | – | 0 | 1 | 2 | 1 | 6 | 22 | 31 | 31 |
| Other non-operating income (expense) | – | – | – | – | – | – | 5 | 21 | 22 | 21 |
| Income before taxes | (4) | (3) | (5) | 0 | 292 | 677 | 184 | (174) | (52) | (70) |
| Income tax expense | 1 | (1) | 0 | 0 | 73 | 175 | 42 | 1 | (8) | (8) |
| Net income from continuing operations | (5) | (3) | (5) | 0 | 219 | 503 | 142 | (175) | (44) | (62) |
| Net income | (5) | (3) | (6) | (0) | 214 | 507 | 143 | (168) | (43) | (61) |
| Net income to common shareholders | (14) | (3) | – | – | – | 507 | 143 | (168) | (43) | (61) |